Table 3. Survival post treatment: Factors associated with time to mortality post treatment.
| Variable | Univariate analysis | Multivariate analysis n = 66 | Multivariate analysis + n = 62 | |||
|---|---|---|---|---|---|---|
| (n) | ||||||
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| Length of treatment (months) | (n = 82) | |||||
| 0–3 | ref | |||||
| 3–6 | 0.61 (0.25–1.55) | 0.30 | 0.91 (0.32–2.62) | 0.87 | 0.83 (0.23–2.97) | 0.78 |
| 6–12 | 0.64 (0.28–1.49) | 0.30 | 0.97 (0.28–3.32) | 0.95 | 0.81 (0.18–3.68) | 0.79 |
| 12+ | 0.11 (0.10–0.77) | 0.03 # | 0.21 (0.02–1.97) | 0.17 | 0.16 (0.01–1.78) | 0.14 |
| Age (years( | (n = 82) | |||||
| 0–25 | ref | |||||
| >25–35 | 3.27 (1.07–9.93) # | 0.04 # | 3.09 (0.96–9.90) | 0.06 | 3.49 (1.06–11.47) # | 0.04 # |
| >35 | 5.08 (1.63–15.79) # | 0.01 # | 3.74 (1.13–12.37) # | 0.03 # | 3.93 (1.04–14.94) # | 0.04 # |
| HIV positive | (n = 79) | |||||
| 0.95 (0.45–2.0) | 0.89 | |||||
| Gender: Male | (n = 82) | |||||
| 1.47 (0.69–3.15) | 0.32 | |||||
| Converted at LFT ** | (n = 66) | |||||
| 0.45 (0.21–1.00) | 0.05 | 0.58 (0.20–1.72) | 0.33 | 0.52 (0.14–1.94) | 0.33 | |
| Resistance pattern | (n = 74) | |||||
| Rifampicin mono resistance | ref | Ref | ||||
| MDR no 2ndline resistance | 0.50 (0.23–1.09) | 0.08 | 0.35 (0.12–0.97) # | 0.04 # | ||
| MDR plus 2ndline resistance | 1.11 (0.31–3.97) | 0.88 | 1.20 (0.21–6.93) | 0.84 | ||
#statistically significant
+Sensitivity analysis-Multivariate analysis including Resistance pattern
**LFT Lost from treatment